Close this search box.

2021 highlights Pivot Park Community

Despite Covid-19 the Pivot Park Community managed to reach many successes in 2021. Pivot Park is very proud of the Community! Read here a short summary of the highlights of our Community members and click on the article to read more:


AdaptVac partners with BioConnection to manufacture their COVID-19 vaccine


License agreement for Glycostem and Ghent University

JanuaryPivot Park

HAN-Lectoraat Drug Discovery komt naar Pivot Park


Certara acquires AUTHOR!

MarchPivot Park

Pivot Park Partner of TU/e Contest

MarchPivot Park Screening Centre

ELF paper selected for print in a special issue of SLAS Discovery


RiboPro raises €1.2M to become leader in (m)RNA


Glycomstem enters into Material Transfer Agreement with Pieris


Citryll Appoints Chief Medical Officer


Vivenics and Tenwise join forces for new Dotmatics applications


New cancer immunotherapy treatment enters clinical phase

MayBioConnectionBioConnection: successful connection with the whole world from Oss
JunePivot ParkProvince gives huge boost to Pivot Park with loan of 37,1 million euros

Investment in Flow Cytometry unlocks the secrets of single cells


InProcess-LSP and DIANT Pharma Inc. finalize Partnership Agreement


Osteo-Pharma receives MREC approval for initiation of clinical trial


GMP certification for new large scale filling line

JulyArdenaCommercial Agency Agreement between Ardena and South Korean company Keyfronbio Co., Ltd.

Pedro Hermkens appointed as Lecturer Drug Discovery

AugustusSynaffixSynaffix announces deal with ProfoundBio providing access to multiple novel linker-payload technologies

Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands


Citryll announced that it has recently secured three grant of patents


Glycostem obtained the Tissue Bank License, to support the production of our lead investigational product oNKord®.


PimBio: 0.5M for iPSC NMJ-on-a-chip model


DIANT Pharma Inc. And InProcess-LSP Finalize Partnership Agreement


PharmaCytics submitted 3 new patents


Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology


Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa


Third ADC with Synaffix’s technology enters clinical development

OctoberNTRC / Oncolines

NTRC Precision Medicine Services is now Oncolines


Osteo-Pharma Announces Strategic Research Collaboration Focused on Accelerating Fracture Healing in Osteoporotic patients


ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation


Ardena has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs.


RiboPro selected partner R3 initiative

NovemberVan Iersle luchtman advocaten

Van Iersel Luchtman Lawyers – Right beside you


Mercurna reached scientific and IP milestones of RMDFII


Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion


Pharming looks forward to settling at Pivot Park


BioConnection to manufacture clinical trial material for Nykode Therapeutics’ vaccine


Osteo-Pharma and Emultech announce joint venture to develop First-In-Class disease-modifying treatment for Osteoarthritis

DecemberPivot Park

Pivot Park ready for start construction Grizzly


NTRC announces IND approval for the TTK/PLK dual inhibitor BAL0891


Publication research paper by Glycostem


RiboPro winner of Blue Tulip Award


Immagene announces seed investment round to progress novel immuno-oncology therapeutics

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.